Ocugen (OCGN), a US biopharmaceutical company, sai
Post# of 716
Covaxin is a whole-virion inactivated COVID-19 vaccine candidate. It has been evaluated in 1,000 subjects in early stage and mid-stage clinical trials in India, with promising safety and immunogenicity data, the companies said. The vaccine candidate is currently part of a late-stage clinical trial in India involving 26,000 volunteers.
Shares of Ocugen surged more than 59% in morning trading.
Price: 0.47, Change: +0.17, Percent Change: +59.12
HOD .8375
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.